当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第15期
编号:13306827
不同配比的哌拉西林—他唑巴坦治疗老年性社区获得性肺炎的疗效对比(1)
http://www.100md.com 2018年4月16日 《医学信息》 2018年第15期
     摘 要:目的 探討不同配比的哌拉西林-他唑巴坦治疗老年社区获得性肺炎的临床疗效。方法 回顾性分析2016年5月~2017年9月在我院治疗的老年CAP患者100例,以随机数表法随机分为华北组和中诺组,每组50例,华北组以3.0 g哌拉西林+0.75 g他唑巴坦(4:1配比)治疗,中诺组以2.0 g哌拉西林+0.25 g他唑巴坦(8:1配比)治疗。用药后在不同时间点分别比较围用药期相关参数、C-反应蛋白和降钙素原、及细菌疗效评价。结果 华北组症状好转时间、住院时间及住院费用均少于中诺组(P<0.05)。两组CRP和PCT用药后较用药前减小(P<0.05),但用药后5 d,华北组CRP和PCT分别为(5.48±2.01)mg/L、(0.12±0.08)ng/L,低于中诺组(6.35±1.88)mg/L、(0.15±0.03)ng/L。华北组清除43例和未清除1例,优于中诺组39例和4例,差异有统计学意义(P<0.05)。华北组和中诺组分别出现用药后不良反应1例和4例。结论 4:1配比和8:1配比哌拉西林-他唑巴坦均能很好的控制老年CAP,但4:1配比能更快的逆转症状,防止感染蔓延,减轻患者痛苦,且缩短住院时间,节省费用,不失为一种性价比高的治疗老年CAP的用药选择。
, 百拇医药
    关键词:社区获得性肺炎;老年;哌拉西林-他唑巴坦

    中图分类号:R563.1 文献标识码:A DOI:10.3969/j.issn.1006-1959.2018.15.041

    文章编号:1006-1959(2018)15-0129-04

    Comparison of the Efficacy of Different Ratios of Piperacillin-tazobactam in Elderly Community Acquired Pneumoni

    XU An-lin,LIU Zhong

    (Department of Pharmacy,Yangzhou Third People's Hospital,Yangzhou 225125,Jiangsu,China)
, 百拇医药
    Abstract:Objective To explore the clinical efficacy of different proportions of piperacillin-tazobactam in the treatment of elderly patients with community-acquired pneumonia.Methods 100 elderly CAP patients who were treated in our hospital from May 2016 to September 2017 were randomly divided into North China group and Zhongnuo group with 50 cases in each group.The North China group was treated with 3.0g piperacillin+0.75g tazobactam(4:1 ratio),and the Zhongnuo group was treated with 2.0g piperacillin+0.25g tazobactam(8:1 ratio).The perioperative parameters,C reactive protein,procalcitonin and bacterial efficacy were compared at different time points.Results The improvement time,length and expenses of hospitalization in the North China group were less than those in the Zhongnuo group(P<0.05).The CRP and PCT of two group decreased after medication (P<0.05),but 5 d after treatment,the CRP and PCT of the North China group were(5.48±2.01)mg/L and(0.12±0.08)ng/L respectively,lower than that of the Zhongnuo group(6.35±1.88) mg/L and(0.15±0.03)ng/L.In the North China group,43 cases were cleared and 1 case were not,better than the Zhongnuo group of which 39 cases cleared and 4 cases not,the difference was statistically significant(P<0.05).There was 1 case of adverse drug reactions in the North China group and 4 cases in the Zhongnuo group.Conclusion Both the 4:1 and 8:1 ratios of piperacillin-tazobactam can control CAP in in the elderly well,but 4:1 can reverse the symptoms more quickly,prevent the spread of infection,alleviate the pain of the patients,shorten the time of hospitalization and save the cost.It is a high cost-effective drug choice for the treatment of elderly CAP., http://www.100md.com(徐安林 刘忠)
1 2 3下一页